Pasatru's FDA Approval Puts Regeneron's Rare-Disease Playbook To The Test

◆ ◆ The Wire takeaway

Regeneron's rare disease strategy now faces real-world regulatory scrutiny, forcing you to rethink how narrow-market drugs gain US approval and commercial traction. Expect tightening FDA expectations to reshape your trial designs and launch timing.